323 related articles for article (PubMed ID: 26246238)
1. Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.
Takemoto ML; Lopes da Silva N; Ribeiro-Pereira AC; Schilithz AO; Suzuki C
Health Qual Life Outcomes; 2015 Aug; 13():119. PubMed ID: 26246238
[TBL] [Abstract][Full Text] [Related]
2. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
[TBL] [Abstract][Full Text] [Related]
4. Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS; Ray S; Ganguli A; Cella D
Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
[TBL] [Abstract][Full Text] [Related]
5. Association between Disability, Cognition, Fatigue, EQ-5D-3L Domains, and Utilities Estimated with Different Western European Value Sets in Patients with Multiple Sclerosis.
Eriksson J; Kobelt G; Gannedahl M; Berg J
Value Health; 2019 Feb; 22(2):231-238. PubMed ID: 30711069
[TBL] [Abstract][Full Text] [Related]
6. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
7. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.
Orme M; Kerrigan J; Tyas D; Russell N; Nixon R
Value Health; 2007; 10(1):54-60. PubMed ID: 17261116
[TBL] [Abstract][Full Text] [Related]
8. Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D).
Goodwin E; Hawton A; Green C
Health Qual Life Outcomes; 2019 Aug; 17(1):136. PubMed ID: 31382960
[TBL] [Abstract][Full Text] [Related]
9. EQ-5D Brazilian population norms.
Santos M; Monteiro AL; Santos B
Health Qual Life Outcomes; 2021 Jun; 19(1):162. PubMed ID: 34112207
[TBL] [Abstract][Full Text] [Related]
10. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
Petrou S; Hockley C
Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
[TBL] [Abstract][Full Text] [Related]
11. Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease.
Bae E; Choi SE; Lee H; Shin G; Kang D
BMC Pulm Med; 2020 Mar; 20(1):73. PubMed ID: 32293387
[TBL] [Abstract][Full Text] [Related]
12. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540
[TBL] [Abstract][Full Text] [Related]
13. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
14. Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample.
Jia H; Zack MM; Moriarty DG; Fryback DG
Med Decis Making; 2011; 31(1):174-85. PubMed ID: 20375418
[TBL] [Abstract][Full Text] [Related]
15. Health Utilities for Multiple Sclerosis.
Hawton A; Green C
Value Health; 2016 Jun; 19(4):460-8. PubMed ID: 27325338
[TBL] [Abstract][Full Text] [Related]
16. Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D.
Fogarty E; Walsh C; Adams R; McGuigan C; Barry M; Tubridy N
Mult Scler; 2013 Aug; 19(9):1190-6. PubMed ID: 23401128
[TBL] [Abstract][Full Text] [Related]
17. Assessment of health state in patients with tinnitus: a comparison of the EQ-5D and HUI mark III.
Maes IH; Joore MA; Cima RF; Vlaeyen JW; Anteunis LJ
Ear Hear; 2011; 32(4):428-35. PubMed ID: 21221004
[TBL] [Abstract][Full Text] [Related]
18. Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis.
Ghajarzadeh M; Jalilian R; Eskandari G; Ali Sahraian M; Reza Azimi A
Disabil Rehabil; 2013 Aug; 35(18):1509-12. PubMed ID: 23237227
[TBL] [Abstract][Full Text] [Related]
19. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
Pickard AS; Gooderham M; Hartz S; Nicolay C
J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
[TBL] [Abstract][Full Text] [Related]
20. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
